LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,250.98
−0.48%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- $5.81
- Revenue estimate
- $22.7B
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $8.38
- EPS estimate
- $6.54
- Revenue actual
- $23.0B
- Revenue estimate
- $20.9B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +20.9%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $1.3K
- PT range
- $940 – $1.5K
- Analysts
- 9
8 Buy0 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $6.54 | $8.38 | Beat 28.10% | $23.0B |
| Apr 30, 2026 | $6.96 | $8.55 | Beat 22.93% | $19.8B |
| Feb 4, 2026 | $7.00 | $7.54 | Beat 7.68% | $19.3B |
| Oct 30, 2025 | $5.62 | $7.02 | Beat 24.96% | $17.6B |
| Aug 7, 2025 | $5.60 | $6.31 | Beat 12.68% | $15.6B |
| May 1, 2025 | $3.26 | $3.34 | Beat 2.45% | $12.7B |
| Feb 6, 2025 | $5.03 | $5.32 | Beat 5.77% | $13.5B |
| Oct 30, 2024 | $1.47 | $1.18 | Miss -19.73% | $11.4B |
| Aug 8, 2024 | $2.60 | $3.92 | Beat 50.77% | $11.3B |
| Apr 30, 2024 | $2.46 | $2.58 | Beat 4.88% | $8.8B |
| Feb 6, 2024 | $2.22 | $2.49 | Beat 12.16% | $9.4B |
| Nov 2, 2023 | -$0.08 | $0.10 | Beat 225.00% | $9.5B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026